HardwareHouston, TX, USAFounded 2018· One of 1740 Hardware companies tracked by AMPulse
Develops vertically integrated 3D bioprinting platforms and materials for manufacturing whole replacement organs.
CEO / Founder
Jordan Miller
Team Size
11-50
Stage
Acquired
Total Funding
$400M
Latest Round
Acquired
Key Investors
Methuselah Foundation; Methuselah Fund; Y Combinator
Technology & Products
Key Products
Proprietary 3D bioprinting technology for fabricating vascularized tissues and organs.
Technological Advantage
Proprietary biomaterials and systems integrated into 3D Systems' portfolio; spin-out from Rice University.
Differentiation
Value Proposition
Reduces the complexity of organ-scale tissue fabrication through a vertically integrated platform of hardware and proprietary biomaterials.
How They Differentiate
Utilizes SLATE (Stereolithography Apparatus for Tissue Engineering) to achieve 20-50 micron resolution for complex vascularization, significantly outperforming the ~100-200 micron resolution of standard extrusion-based systems like CELLINK BIO X. The process uses visible light and food-dye photoinitiators, reducing cytotoxicity compared to UV-based systems.
Market & Competition
Target Customers
Medical researchers and regenerative medicine companies
Industry Verticals
Medical; Regenerative Medicine
Competitors
CELLINK, Organovo
Growth & Milestones
Growth Metrics
2019 Revenue: $1.5 million; Acquired for up to $400 million in 2021.
Major Milestones
2018: Founded as Rice University spin-out; 2019: Achieved $1.5M revenue; 2020: Participated in Y Combinator; 2021-10: Acquired by 3D Systems for $400M
Volumetric addresses the challenge of manufacturing whole replacement organs by combining proprietary hardware and biomaterials into a vertically integrated platform. Its SLATE (Stereolithography Apparatus for Tissue Engineering) technology achieves 20-50 micron resolution for complex vascularization, outperforming the 100-200 micron resolution typical of extrusion-based systems like CELLINK BIO X. The process uses visible light and food-dye photoinitiators, reducing cytotoxicity compared to UV-based alternatives.
Target customers include medical researchers and regenerative medicine companies. Notable partners include United Therapeutics and Lung Biotechnology PBC. Volumetric was acquired by 3D Systems in October 2021 for up to $400 million, following participation in Y Combinator and support from the Methuselah Foundation.
The company's competitive moat lies in its integrated hardware-software-biomaterials approach and its SLATE technology's ability to produce organ-scale vascularized tissue. Key risks include the long regulatory and clinical pathway for whole organ replacement and competition from established bioprinting firms like Organovo and CELLINK. The acquisition by 3D Systems provides access to broader distribution and manufacturing resources.